Abstract

FORMULATION AND EVALUATION OF BILAYER SUSTAIN RELEASE TABLET OF ALLOPURINOL AND TELMISARTAN FOR THE TREATMENT OF HYPERURICEMIA ASSOCIATED WITH HYPERTENSION

Navesh Veer*, Lal Ratnakar Singh and Lalit Kumar Tyagi

ABSTRACT

Bilayer tablets are basically used to administer a dosage form with dual release effect or to formulate two incompatible drugs. Present research work involves the development of a bi-layer sustain release tablet of Telmisartan and Allopurinol by using polymers like HPMC and microcrystalline cellulose. The prepared bi-layer tablet contains Telmisartan as immediate release layer and Allopurinol as sustained release layer. The best composition of immediate release and sustained (sustain release) part of the bilayer tablet were A3 and B3 respectively. The selection is based on the best dissolution profile of suited for the release of both the drugs. FTIR analysis shows no interaction between these drugs and excipients. The bi-layer tablets of Telmisartan and Allopurinol were prepared by the direct compression method. Hyperuricemia is defined as a serum urate level greater than 6.0 mg/dl in women, and 7.0 mg/dl in men. Gout is due to the nucleation and growth of monosodium urate (MSU) crystals in tissues in and around the joints, following long-standing hyperuricemia, that is, serum urate (sUA) above the saturation threshold. Hyperuricemia results from an imbalance between the rate of production and excretion of uric acid in the body. When the blood pressure stays elevated over time, hypertension develops. Hypertension is usually defined as a systolic pressure above 140 mm Hg and a diastolic pressure above 90 mm Hg. Thus, the

Keywords: prepared formulation is used for the patient suffering with co-morbid condition of hyperuricemia associated with hypertension.